Citigroup upgraded Evotec SE from Neutral to Buy
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/24/2025 | Sell → Hold | Deutsche Bank | |
| 10/7/2024 | Buy → Hold | Jefferies | |
| 8/8/2024 | Hold → Sell | Deutsche Bank | |
| 7/29/2024 | $15.00 → $6.00 | Overweight → Equal-Weight | Morgan Stanley |
| 7/11/2024 | Buy → Hold | Deutsche Bank | |
| 4/12/2024 | Hold → Buy | Deutsche Bank | |
| 1/18/2024 | Sector Perform → Outperform | RBC Capital Mkts | |
| 6/23/2023 | $12.00 → $16.00 | Equal-Weight → Overweight | Morgan Stanley |
Deutsche Bank upgraded Evotec SE from Sell to Hold
Jefferies downgraded Evotec SE from Buy to Hold
Deutsche Bank downgraded Evotec SE from Hold to Sell
Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies HAMBURG, GERMANY / ACCESSWIRE / September 26, 2024 / Evotec SE ((Frankfurt Stock Exchange:EVT, SDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) announced today that Evotec has entered a technology development partnership with Novo Nordisk in cell therapy.Both Evotec and Novo Nordisk have significant expertise and a strategic focus to support stem cell-based therapies. In order to provide next-generation off-the-shelf cell therapy products for clinical development and possible commercialisation thereafter, the companies will collaborate on developm
Most agenda items adopted with great majorityAnnual General Meeting 2024 elects Dr Duncan McHale and Wesley Wheeler to the Supervisory Board, replacing Dr Elaine Sullivan and Dr Mario PolywkaHAMBURG, GERMANY / ACCESSWIRE / June 10, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((MDAX/TecDAX, OTC:EVOTF)(NASDAQ:EVO) today announced that its shareholders approved most of the proposals the Company's Management put to vote at the Company's Annual General Meeting 2024 with great majority.Under the topic "Together for Medicines that Matter - Weg zum Neustart", the Chairperson of the Supervisory Board of Evotec SE, Prof. Dr Iris Löw-Friedrich, Chief Business Officer Dr Matthias Evers and Chief Fina
HAMBURG, GERMANY / ACCESSWIRE / April 23, 2024 / The Supervisory Board of Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) has appointed Dr Christian Wojczewski as the Company's new Chief Executive Officer ("CEO"), effective 01 July 2024. The election was unanimous and is the result of an extensive selection process that began in January.Dr Mario Polywka, who has led Evotec as Interim CEO since 03 January 2024, will retire from his position at the end of June and will also not seek re-election for his dormant Supervisory Board mandate, which expires with the 2024 Annual General Meeting.Dr Christian Wojczewski holds a degree in chemistry and has over 20 years of
Yonsei University, Zymedi and Evotec receive US$ 4.5m grant from the Korea Institute of Advanced Technology under the Korean Ministry for Trade, Industry and EnergyFunding supports a novel collaboration to develop first-in-class therapeutic antibodies to treat asthma and idiopathic pulmonary fibrosis HAMBURG, GERMANY / ACCESS Newswire / January 22, 2025 / Evotec SE ((Frankfurt Stock Exchange:EVT, MDAX/TecDAX, TRQX:EVTd, NASDAQ:EVO) announced that, together with Yonsei University and the Korean biotech company Zymedi, it will receive a US$ 4.5m grant from the Korea Institute of Advanced Technology (KIAT). The KIAT grant will fund the development of first-in-class biologic therapies to treat l
Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on cardiometabolic diseasesLAB eN² is also expanding, adding Boston Children's Hospital, Boston University, Johns Hopkins University, Joslin Diabetes Center, and the Icahn School of Medicine at Mount Sinai as new participating institutions HAMBURG, DE / ACCESSWIRE / December 11, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((SDAX/TecDAX, TRQX:EVTd)(NASDAQ:EVO) announced that its translational drug discovery accelerator with Novo Nordisk, LAB eN², which aims to nurture early research from acade
Dr Craig Johnstone steps down as Chief OperatingOfficer effective 31 December 2024Distribution of responsibilities internally HAMBURG, GERMANY / ACCESSWIRE / November 29, 2024 / Evotec SE ((Frankfurt Stock Exchange: EVT, SDAX/TecDAX, TRQX:EVTd, NASDAQ:EVO) today announced that its Chief Operating Officer, Dr Craig Johnstone, will step down and leave the Company effective 31 December 2024. Dr Johnstone joined Evotec in May 2012 as SVP Drug Discovery and Innovation Efficiency and in April 2015 was named President and Site Head, Evotec (France) SAS. Dr. Johnstone was appointed Global Head, Integrated Drug Discovery in January 2017 and became Chief Operating Officer and a member of the Managemen